Price movement over the last 24 hours
ADMA Biologics Inc vs Williams Companies Inc — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Williams Companies Inc trades at $75.11 (market cap $91.82B). The key difference: Williams Companies Inc is far larger — about 43.1× ADMA Biologics Inc's market cap, and Williams Companies Inc pays a 2.8% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WMB | |
|---|---|---|
Market Cap | $2.13B | $91.82B |
Sector | Health | Energy |
52-Week High | $20.38 | $79.40 |
52-Week Low | $7.60 | $56.51 |
Enterprise Value | $2.20B | $121.21B |
Dividend Yield | — | 2.8% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Williams Companies (WMB) trades at $75.08, up 2.65% on the day, approaching its 52-week high of $80.08. The stock shows strong profitability with a 23.4% net income margin and 21.95% ROE, though valuation ratios like P/E of 31.94 appear elevated. Recent news highlights a potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure, while technical indicators signal a bearish trend despite neutral oscillators.
WMB presents a mixed outlook: robust cash flow growth and a 79% analyst buy rating support upside to the $86.55 consensus target, but high debt levels and recent earnings misses pose risks. The stock's current price near resistance at $75 suggests near-term consolidation, with long-term growth hinging on successful integration of acquisitions and stable energy demand.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →